Items in BOLD are required.
Page 2
Page 3

Physician Focus on Parkinson's

Issue 20 (Winter 2011) - Quarterly CME Newsletter on Parkinson's Disease

To receive CME credit for this activity, please complete the post-test and evaluation below. You must score 70% or better on the post-test in order to receive your CME certificate. Once submitted, a certificate will be issued within two weeks to the email address provided.

Click here to view Issue 20 online.

If you have any questions, please contact intellyst® Medical Education at 720-748-8800.

Target Audience
Neurologists, NPs and PAs specializing in neurology, and other healthcare professionals who treat patients with Parkinson's disease.

Statement of Need

Parkinson’s disease (PD) has traditionally been classified as a movement disorder as its cardinal symptoms include tremor, rigidity, slowed movement and postural instability. However the importance of psychiatric and other non-motor symptoms (NMS) in the detection of disease and their impact on quality of life has forced clinicians to envision PD as a complex disorder that requires careful and thorough evaluation throughout their patients’ lifetimes. It is necessary to understand that NMS often present early in disease, and it is the worsening of these symptoms that may spur individuals to seek medical attention. With disease progression, these symptoms invariably become more debilitating and are a clinical challenge to control over the long run. In addition to dopaminergic therapy, patients may require additional pharmacologic agents to control symptoms, adding to their burden of cost and complexity as they seek to sustain quality of life.

Learning Objectives
At the conclusion of this activity, participants should be able to:
- Discuss recent findings regarding the relationship between alpha-synuclein uptake and Lewy body formation
- Describe the rationale for GAD-AAV gene therapy, and the results from the blinded trial
- Describe recent clinical studies:
  • the possible clinical consequences of the genetic difference between COMT encoding either valine or methionine
  • botulinum toxin type B’s ability to reduce drooling in PD patients
  • the rationale for and results from the recent trial of implanted retinal epithelial cells
  • evidence for the long-term effectiveness of DBS on PD patients
Robert Hauser, MD (Case Study Contributor)
Gary VanderArk, MD (Independent Reviewer)
Richard Robinson (Medical Writer)

Accreditation Statement
intellyst® Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
intellyst® Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.